

ABBVIE LTD ABPI DISCLOSURE REQUIREMENTS ON TRANSFERS OF VALUE TO PATIENT ORGANISATIONS FOR FINANCIAL YEAR 2024

Name of Patient Organisation	Financial Support Grant	Financial Support Sponsorship	Service Fee	Service Expense	Short Description of Activity (Objective)
Allergy UK	£5,000.00				Funding towards social media activity
Arthritis and Musculoskeletal Alliance (ARMA)		£7,000.00			Corporate membership
Arthritis Action	£5,000.00				Funding towards webinar series
Arthritis Action			£405.00		Participation in advisory board
Axial Spondyloarthritis International		£34,245.06			Corporate membership
Axial Spondyloarthritis International		£12,666.07			Funding towards Council Meeting
Bladder Health UK	£5,500.00				Funding towards website updates
Blood Cancer Alliance		£15,000.00			Industry Partner Funding towards Blood Cancer Alliance
Blood Cancer UK			£472.50		Presentation at internal AbbVie meeting
Blood Cancer UK	£25,000.00				Funding towards Support Service Transformation
Cancer 52		£10,000.00			Corporate membership
Crohn's and Colitis UK	£10,000.00				Funding towards IBD dashboard development
Cerebra	£9,424.00				Funding towards equipment for children with brain conditions
CLL Support Association	£20,000.00				Funding towards Education, Wellbeing and Advocacy Programme

CLL Support Association		£337.50		Presentation at internal AbbVie meeting
CLL Support Association		£472.50	£58.70	Presentation at Frontiers event
Disability Support	£1,400.00			Funding towards 1:1 support for disabled adults
Dystonia UK	£5,000.00			Funding towards animation development
Eczema Outreach		£425.00		Review of Abbvie generated and funded report
Eczema Outreach	£15,000.00			Funding to support ongoing improvements in patient care
Edinburgh Young Carers	£7,500.00			Funding towards specialist counselling service
Get Your Belly Out	£5,000.00			Funding to support ongoing improvements in patient care
Glaucoma UK		£3,500.00		Funding towards UKEGS congress sponsorship
Headway Nottingham	£2,000.00			Funding towards workshop costs
Headway Surrey	£1,200.00			Funding towards continuation of young person's group
Hepatitis C Trust	£20,000.00			Funding towards HCV Action 2024 workplan
HIV i-Base		£862.50		Presentation at external AbbVie meeting
HIV i-Base		£360.00		Consultancy services relating to HIV clinical study materials
HIV i-Base		£120.00		Individual consultancy to provide insights into HIV burden
IBDrelief		£303.75	£159.00	Presentation at internal AbbVie meeting
IBDrelief		£405.00	£67.90	Participation in advisory board
International Agency for the Prevention of Blindness		£89,644.27		Corporate membership
International Agency for the Prevention of Blindness		£25,000.00		Funding towards awareness day sponsorship
International Agency for the Prevention of Blindness		£78,250.00		Funding towards DME Coalition activity
International Agency for the Prevention of Blindness		£10,995.00		Services relating to DME Coalition activity
Kidney Research UK	£2,000.00			Funding towards supporting children following transplant

Leukaemia Care	£20,000.00			Funding towards Patient Information Provision
Leukaemia UK	£10,000.00			Funding towards leukaemia diagnostic pathway project
Lymphoma Action	£25,000.00			Funding towards Patient information and support
Lymphoma Action		£1,282.50	£79.10	Participation in DLBCL patient education video series
Macular Society	£5,000.00			Funding towards Clinical Trials Network Feasibility
National Axial Spondyloarthritis Society		£637.50		Presentation at external conference
National Axial Spondyloarthritis Society	£30,000.00			Funding towards Aspiring to Excellence programme
National Eczema Society		£762.50		Review of Abbvie generated and funded report
National Eczema Society	£20,000.00			Funding to support ongoing improvements in patient care
National Voices		£49,750.00		Funding to support improved patient outcomes
Neurological Alliance		£160.00		Attendance at AbbVie internal meeting
Neurological Alliance		£12,045.00		Membership of industry reference group
National Rheumatoid Arthritis Society		£438.75		Presentation at external conference
National Rheumatoid Arthritis Society	£9,875.00			Funding towards video production
Parkinson's Europe		£47,078.33		Corporate membership
Parkinson's Europe		£48,175.23		Funding towards Parkinson's Europe policy activities
Parkinsons UK		£607.50		Participation in roundtable
Patients Association		£13,052.00		Co-ordination of virtual panel event
Patients Association	£15,000.00			Funding to support ongoing improvements in patient care
Psoriasis Association			£77.60	Expenses relating to roundtable participation
Psoriasis Association		£2,000.00		Corporate membership
Psoriasis Association		£6,000.00		Funding to support ongoing improvements in patient care
Retina UK	£5,000.00			Funding towards Sight Loss Survey
SOFT UK	£3,874.00			Funding towards equipment and accessories

The Migraine Trust	£30,878.00	Funding to support policy awareness-raising
The Migraine Trust	£14,893.00	Funding towards migraine patient videos
The Tuberous Sclerosis Association	£4,000.00	Funding towards specialist creche facilities for disabled children
The Wren Project	£405.00	Participation in advisory board

ABBVIE LTD TRANSPARENCY DISCLOSURE METHODOLOGICAL NOTES FOR REPORTING YEAR 2024

As a member company of European Federation of Pharmaceutical Industries and Associations (EFPIA) and Association of the British Pharmaceutical Industry (ABPI), **AbbVie Ltd** is committed to ensuring that the nature and scope of partnerships and transfers of value (ToV) to Patient Organisations are clear and transparent to the public. Therefore, AbbVie Ltd has published applicable ToV provided directly or indirectly to Patient Organisations for the 2024 calendar year.

This Methodological Note provides guidance on how AbbVie Ltd has recorded and publicly reported this information in accordance with the current edition of the ABPI Code of Practice.

Reporting period/Reportable ToV:

The AbbVie Ltd 2024 disclosure includes applicable ToV during the period between 1st January and 31st December 2024. The applicable ToV relate to payments made within the disclosure period. Payments made from 1st January 2025 will be considered for the next report.

Defining Reportable Organisations:

The ABPI definition of Patient Organisations is broad, so additional factors were taken into consideration when determining whether ToV to organisations were reportable under the category of Patient Organisation.

These included but were not limited to the following in relation to a health condition or disability: provision of information and support services, hosting of campaigns and events to raise awareness, involvement in policy activities to improve patient outcomes, community engagement and provision of other support related to patients' healthcare, except where activities were delivered based on AbbVie's confidential contractual obligations in relation to third parties that are not Patient Organisations (e.g., the NHS).

Transparency Acknowledgment from Patient Organisations:

Agreements between AbbVie Ltd and Patient Organisations relating to ToV have a Transparency section which includes notification of AbbVie's Transparency disclosure obligations.

Validation Approach:

AbbVie has conducted a validation exercise with Patient Organisations contained within this reporting period to make them aware of the disclosure and provide an opportunity to verify any ToV.

Cross Border Interactions:

These ToV include engagements between AbbVie Global/Europe and UK Patient Organisations where these have occurred. For example, where a Patient Organisation has participated in an AbbVie Global/European programme or activity.

National Contracts and Tenders:

AbbVie does not disclose transfers of value related to national contracts or tenders. These arrangements are awarded through competitive procurement processes and maintaining confidentiality is essential to ensuring a fair competitive market while maintaining our compliance obligations.

ToV Definitions:

Each ToV includes a category label and brief description of the activity it relates to. The category and associated descriptors are as follows:

- Financial Support, including Grants, Sponsorships and Services:
 - Grants:
 - Definition: Funding provided by AbbVie, in whole or in part, for activities carried out by a Patient Organisation, including project-specific or core funding, for the purpose of supporting healthcare, scientific research or education, with no consequent obligation on the patient organisation to provide goods or services in return.
 - Examples: unrestricted grants for the development of patient materials
 - Sponsorship:
 - Definition: Financial or non-financial support provided in whole or in part, by AbbVie for activities carried out by a Patient Organisation for the purpose of supporting healthcare, scientific research or education. Sponsorships are provided at an arm's length arrangement without AbbVie's involvement in the activities or the development of any associated content event/meetings or other materials. AbbVie may receive benefits as agreed with the patient organisation e.g. invitations to appropriate events, 'early bird' access to project / activity results and insights.
 - Examples: Sponsorship of educational material, sponsorship of webinars/events.
 - Services:
 - Definition: Services provided by the Patient Organisation to AbbVie, including fees and expenses in relation to the services delivered
 - Examples: Participation in or speaking at an AbbVie meeting or Advisory Board, review of AbbVie materials for patients.

Fees and expenses have been disclosed separately. This includes expenses such as transport or accommodation costs incurred to take part in the associated activity, including those activities that were reimbursed or paid directly by AbbVie.

All services are remunerated at Fair Market Value.

Value Added Tax (VAT):

Where applicable, disclosure of payments does not include VAT.

Currency:

All information is reported in Pound Sterling (GBP).

Exchange Rate:

Where ToV were captured in foreign currency, amounts were converted to local currency based on AbbVie Ltd Treasury Monthly Average Rates.

Multi-year Contracts:

Activities with ToV crossing calendar years may have the contracted full amount disclosed using the date of last payment.

Post Publication Disputes:

AbbVie will review and investigate disputes with Patient Organisations relative to our disclosures. Any changes resulting from this review will be published in an updated report.